Literature DB >> 30117117

Author's Reply to Webster and Woollett: "The End of Phase 3 Clinical Trials in Biosimilars Development?"

Francois-Xavier Frapaise1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 30117117     DOI: 10.1007/s40259-018-0298-x

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


× No keyword cloud information.
  1 in total

1.  An Efficient Development Paradigm for Biosimilars.

Authors:  Christopher J Webster; Anny C Wong; Gillian R Woollett
Journal:  BioDrugs       Date:  2019-12       Impact factor: 5.807

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.